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Abstract: Polyphenols are plant secondary metabolites with diverse biological and potential 
therapeutic activities such as antioxidant, anti-inflammatory and anticancer, among others. 
However, their extraction from the native plants is not enough to satisfy the increasing demand for 
this type of compounds. The development of microbial cell factories to effectively produce 
polyphenols may represent the most attractive solution to overcome this limitation and produce 
high amounts of these bioactive molecules. With the advances in the synthetic biology field, the 
development of efficient microbial cell factories has become easier, largely due to the development 
of the molecular biology techniques and by the identification of novel isoenzymes in plants or 
simpler organisms to construct the heterologous pathways. Furthermore, efforts have been made to 
make the process more profitable through improvements in the host chassis. In this review, 
advances in the production of polyphenols by genetically engineered Saccharomyces cerevisiae as well 
as by synthetic biology and metabolic engineering approaches to improve the production of these 
compounds at industrial settings are discussed. 
Keywords: polyphenols biosynthesis; synthetic biology; Saccharomyces cerevisiae; metabolic 
engineering; heterologous production 
 
1. Plant Polyphenols 
The secondary metabolism refers to the metabolic pathways that lead to the compounds that are 
not involved in the processes of growth, development and reproduction [1]. Plants produce diverse 
secondary metabolites including phenolics, terpenes and steroids, and alkaloids that are stored in 
specific organelles at low concentrations [2]. These compounds are responsible for the plant 
adaptation against biotic and abiotic stresses and have a wide range of applications as 
pharmaceuticals, cosmetics and fine chemistry, among others [2,3]. 
Phenolics are a large group of plant secondary metabolites characterized by containing at least 
one hydroxylated aromatic ring. This group includes the hydroxycinnamic acids, such as p-coumaric 
acid, caffeic acid and ferulic acid. These compounds are the precursors of complex polyphenolic 
molecules whose expected market value is USD 2.26 billion by 2027 [4]. Polyphenols can be divided 
in flavonoids, stilbenoids, curcuminoids, coumarins, polyphenolic amides and lignans. Some of these 
compounds are more documented and studied, namely flavonoids, stilbenoids and curcuminoids 
(Figure 1). For example, flavonoids (expected market value: 1.26 billion USD by 2026 [5]) are the most 
studied subgroup with more than 4000 varieties identified. Regarding stilbenoids, the resveratrol 
(expected market value: 149.43 million USD by 2027 [6]) found in grapes is the most well documented. 
Curcuminoids are plant-specific polyphenols produced by Zingiberates order species such as the 
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Curcuma longa and are widely used as dietary spice, and curcumin is the one most explored due to 
its suggested superior biological activities (expected market value: 151.9 million USD by 2027 [7]). 
  
Figure 1. Chemical structure of some polyphenols. 
1.1. Biological Activities 
Plant polyphenols have shown numerous biological activities [8–13] and, in recent decades, 
several epidemiological studies were carried to elucidate their therapeutic effects against several 
human diseases or conditions. The most reported characteristic for polyphenols is their capacity to 
scavenge reactive oxygen species (ROS) and to inhibit other oxidative damages such as lipid 
oxidation, hydroperoxide formation and DNA damage in the human body. At the cellular level, 
polyphenols may act as antioxidants through their effect on plasma membranes, transcription factors 
and in the enzyme activity. This chemical reactivity is conferred by the hydroxyl groups attached to 
the benzene group which confers a stronger acidic character to phenol [14]. For example, the 
antioxidant activity of rosmarinic acid and salvionic acid were determined using 2,2-diphenyl-1-
picrylhydrazyl radical scavenging by Zhang et al. [15] and these two polyphenols were classified as 
strong antioxidant molecules. More specific tests have already been used to prove the antioxidant 
effect of polyphenols in the human body. For instance, Gallardo et al. [16], tested the in vitro 
protective effect of resveratrol against the oxidation caused by hypochlorous acid (HClO) in red 
blood cells, using thermal fluctuation spectroscopy to measure the fluctuations in the cell’s 
membrane. The researchers suggested that the treatment with resveratrol resulted in a protective 
effect against oxidation since the deformation of the red blood cells decreased when the resveratrol 
treatment was applied. Moreover, in vivo tests have also been performed. García-Alonso et al. [17] 
evaluated the short-term effect of phenolic rich juice on the antioxidant status of healthy human 
subjects. The results indicated that polyphenols were able to bind the lipid content of serum and 
consequently reduce lipid peroxidation. 
In addition, polyphenols have shown anticancer effects against various carcinomas. These 
compounds have several mechanisms of action targeting from DNA mutations to metastasis and 
apoptosis processes [13]. Moreover, other therapeutic effects have been reported such as anti-
inflammatory, anti-Alzheimer, anti-Parkinson, anti-diabetic or anti-HIV effects. Table 1 summarizes 
examples of biological activities and the respective mechanisms of action of some polyphenols. 
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Table 1. Biological activities of some polyphenols. 
Biological 
Activity Mechanism of Action References 
Anticancer 
 Curcumin and quercetin reduce the number and size of adenomas in patients with 
familial adenomatous polyposis. 
 Curcumin treatment in patients with colorectal cancer improves the expression of 
p53 tumor suppressor and modulates the expression of the apoptosis-related 
molecules Bax and Bcl-2 inducing cells apoptosis. 
 Curcumin and quercetin modulate the breast cancer type 1 susceptibility protein 
(BRCA1) levels and inhibit the migration and survival of triple negative breast 
cancer cells. 
 Resveratrol inhibits proliferation-related proteins and cell proliferation in 
nasopharyngeal carcinoma cells. 
 Quercetin increases FasL mRNA expression and p51, p21 and growth arrest and 
DNA damage-inducible 45 proteins signaling activities inducing apoptosis and cell 
cycle arrestment in triple negative breast cancer cells. 
 Proanthocyanidins modulate the expression of miRNA inhibiting the proliferation 
of pancreatic cancer cells. 
 Naringenin eliminates the migration and evasion of glioblastoma cells through the 
inhibition of matrix metalloproteinases, estrogen receptor (ER) and p38 activities 
and the modulation of epithelial–mesenchymal transition markers. 
[18–22] 
Anti- 
inflammatory 
 Curcuminoid–piperine administration in patients with metabolic syndrome 
decreases C-reactive protein concentrations in plasma. 
 Naringenin inhibits both inflammatory pain and neurogenic inflammation. The 
mechanism involves the inhibition of carrageenan-induced oxidative stress, 
hyperalgesic cytokines production and nuclear factor kappa- B activation. 
 Curcumin increases the production of anti-inflammatory cytokines in microglial 
cells. 
[23–25] 
Antiviral 
 Genistein blocks a late-phase event in the life cycle replication of Herpes B virus 
reducing virus replication and spread.  
 Resveratrol inhibits the viral multiplication of pseudorabies virus in host cells.  
[26,27] 
Antimicrobial 
 Polyphenols exhibit antimicrobial effects against both Gram-negative and Gram-
positive bacteria. The destabilization of the outer membrane of Gram-negative 
microorganisms, as well as interactions with the cell membrane might be one of the 
specific mechanisms behind the antibacterial action.  
 Several polyphenols suppress microbial virulence factors. The reduction of host 
ligands adhesion, inhibition of biofilm formation and the neutralization of bacterial 
toxins has been demonstrated. In addition, a synergism between polyphenol and 
antibiotics has been observed.  
[28,29]  
Anti-ageing 
 Resveratrol administration in patients with mild–moderate Alzheimer’s disease 
decreases matrix metalloproteinase 9 levels and induces immune responses that 
increase the brain resistance to amyloid precursor protein/β-amyloid deposition. 
 Curcumin administration in non-demented adults results in memory and attention 
improvements due to the lower accumulation of amyloid and tau in the brain. 
 Orally administered flavonoid rutin significantly attenuates memory deficits in 
Alzheimer’s disease in transgenic mice by interaction with amyloid β peptides.  
[30–32] 
Estrogenic 
 8-prenylnaringenin administration in post-menopausal women exhibits positive 
effects in the reduction of menopausal discomforts.  
 8-prenylnaringenin promotes bone formation and inhibits the loss of bone density 
by interacting with ERα in postmenopausal osteoporosis. These effects are more 
potent than the effects of other phytoestrogens (genistein and daidzein). 
[33,34] 
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1.2. Polyphenol Biosynthesis 
There are two biosynthetic pathways involved in the polyphenol biosynthesis in plants, namely 
the shikimate pathway and the phenylpropanoid pathway. A schematic representation of the 
phenylpropanoid biosynthesis is illustrated in Figure 2.  
 
Figure 2. Pathways involved in the polyphenol biosynthesis. 4CL—4-coumarate-CoA ligase; C4H— 
cinnamate-4-hydroxylase; CM—chorismate mutase; CS—chorismate synthase; DAHP—3-deoxy-D-
arabino-heptulosonate-7-phosphate; DAHPS—3-deoxy-D-arabino-heptulosonate-7-phosphate 
synthase; DHQ—3-dehydroquinate dehydratase; DHQS—3-dehydroquinate synthase; E4P—D-
erythrose-4-phosphate; EPSPS—5-enolpyruvylshikimate 3-phosphate synthase; HPP-AT—4-
hydroxyphenylpyruvate aminotransferase; PAL—phenylalanine ammonia lyase; PDC—
phenylpyruvate decarboxylase; PDH —prephenate dehydrogenase; PDT—prephenate dehydratase; 
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PEP—Phosphoenolpyruvic acid; PPY-AT—phenylpyruvate aminotransferase; SDH—shikimate 
dehydrogenase; SK—shikimate kinase; TAL—tyrosine ammonia lyase. 
The shikimate pathway consists of seven sequential enzymatic steps. The first one is the 
condensation of phosphoenolpyruvic acid (PEP) and D-erythrose-4-phosphate (E4P). These two 
phosphorylated active compounds are derived from the glycolytic pathway and the pentose 
phosphate cycle, respectively. The last reaction of this pathway is catalyzed by chorismate mutase 
(CM) to form chorismate. Then, chorismate is converted into the aromatic amino acids, phenylalanine 
and tyrosine, by successive reactions [35]. 
Subsequently, the phenylpropanoid pathway channels the carbon flow from amino acid 
metabolism to different branch pathways of secondary metabolism which include the synthesis of the 
diverse polyphenols. Phenylalanine ammonia lyase (PAL) is the first enzyme of this pathway and it 
represents a branch point between primary and secondary metabolism. It catalyzes the formation of 
cinnamic acid. Then, cinnamic acid is converted to p-coumaric acid by cinnamate-4-hydroxylase (C4H). 
Alternatively, tyrosine can also be used as an initial substrate of the pathway. In this reaction, tyrosine 
is directly converted into p-coumaric acid by tyrosine ammonia lyase (TAL). Afterwards, p-coumaric 
acid can be metabolized in two different ways. It may be converted to other hydroxycinnamic analogues 
or it can be activated to form the coenzyme A (CoA) ester (Figure 3). The production of p-coumaroyl-
CoA is catalyzed by 4-coumarate-CoA ligase (4CL). This enzyme acts in multiple substrates, activating 
also the other analogues. After activation, p-coumaroyl-CoA can also be converted into the other 
activated analogues, caffeoyl-CoA and feruloyl-CoA. At this point the polyphenol biosynthesis 
diverges and the enzymes involved depend on the type of polyphenol produced. 
Afterwards, some of the reactions are catalyzed by a group of enzymes called type III polyketide 
synthase (PKS) and despite their structural simplicity, type III PKSs produce a wide array of 
compounds [36]. There are several varieties and each one catalyzes the formation of a different 
polyphenol or a polyphenol group. Type III PKSs use the activated CoA esters (such as p-coumaroyl-
CoA) as starter units and malonyl-CoA molecules as extender units [36]. For instance, the first step in 
flavonoid biosynthesis is performed by chalcone synthase (CHS). This enzyme catalyzes the formation 
of naringenin chalcone from p-coumaroyl-CoA and three molecules of malonyl-CoA. Afterwards, 
naringenin chalcone is converted into naringenin by chalcone isomerase (CHI). Subsequent reactions 
are responsible for the synthesis of other specific flavonoids resulting in the chemodiversity of these 
compounds [37]. Other type III PKSs include stilbene synthase (STS), diketide-CoA synthase (DCS), 
curcuminoid synthase (CUS) and curcumin synthase (CURS). In the polyphenolic amides pathway, the 
CoA esters are converted into amides such as avenanthramide by hydroxycinnamoyl-
CoA:shikimate/quinate hydroxycinnamoyl transferase (HCT), and there is no proof so far that malonyl-
CoA acts as an extender substrate [38]. Regarding coumarins, they can also originate from the three 
CoA esters by the action of p-coumaroyl-CoA 2’-hydroxylase (C2’H) [39]. The lignans pathway starts 
through the dimerization of two molecules of coniferyl alcohol that are produced after two enzymatic 
steps from feruloyl-CoA [40]. As far as we know, there have been no studies reporting the heterologous 
production of coumarins, curcuminoids and lignans in S. cerevisiae. 
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Figure 3. Steps involved in the hydroxycinnamic acids, flavonoids, stilbenoids, polyphenolic amides 
and curcuminoids biosynthesis from p-coumaric acid. 3GT—anthocyanidin 3-O-glycosyltransferase; 
4CL—4-coumarate-CoA ligase; AAT—anthocyanin acyltransferase; AMT—anthocyanin 
methyltransferase; ANS—anthocyanidin synthase; C3H—4-coumarate 3-hydroxylase; COMT—
caffeic acid 3-O-methyltransferase; CCoAOMT—caffeoyl-CoA 3-O methyltransferase; CHI—
chalcone isomerase; CHS—chalcone synthase; CS3’H—p-coumaroyl 5-O-shikimate 3’-hydroxylase; 
CST—p-coumaroyl shikimate transferase, CURS—curcumin synthase; CUS—curcuminoid synthase; 
DCS—diketide-CoA synthase; DFR—dihydroflavonol 4-reductase; F3H—flavanone 3-hydroxylase; 
F3′H—flavonoid 3′-hydroxylase; F3′5′H—flavonoid 3′5′-hydroxylase; FLS—flavonol synthase; FNS—
flavone synthase; HCT—hydroxycinnamoyl-CoA: Shikimate/quinate hydroxycinnamoyl transferase; 
IFS—isoflavone synthase; LAR—leucoanthocyanidin 4-reductase; ROMT—resveratrol O-
methyltransferase; STS—stilbene synthase. 
1.3. Polyphenol Heterologous Production  
Given all the benefits of plant polyphenols, the production of larger quantities of these 
compounds is important to satisfy the demand and to enable a deeper study of their health-
promoting effects. However, plant secondary metabolites are accumulated in low quantities and vary 
widely among different plant species and tissues. Moreover, the availability of these compounds is 
affected by seasonal and geographical variations. Their extraction from the native plants is 
characterized by low yields and complex downstream processes [41]. Besides, many plants 
containing high-value compounds are difficult to cultivate, and over harvesting may result in their 
depletion. The chemical synthesis could represent a fast way to synthesize them. However, it requires 
the use of expensive precursors, toxic catalysts and extreme reaction conditions. Therefore, the 
process is neither amenable for a large-scale production nor eco-friendly [42]. 
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The heterologous production in plants is an alternative approach to obtain these valuable 
compounds. This approach has the advantage of requiring the introduction of less genes since the 
phenylpropanoid pathway is already present. However, plants possess competitive pathways that 
could greatly interfere with the polyphenol biosynthesis. Moreover, these heterologous plants also 
take a long time to grow and the growth is dependent on weather conditions and on fertile land 
availability. In addition, they are difficult to genetically manipulate. The use of plant cell cultures, 
although being a way to overcome those limitations, has also some disadvantages such as 
heterogeneity, variable yields, low growth rates, unstable cultures, susceptibility to stresses and 
aggregation [43]. The reconstruction of the biosynthetic pathways in microorganisms could be an 
alternative method to meet the industrial requirements for polyphenol production. The use of 
engineered microorganisms represents a promising strategy towards a more rapid, inexpensive and 
green process. Genetically modified microorganisms have several advantages since they can grow in 
inexpensive substrates, are easier to manipulate and have fast production cycles allowing a faster and 
larger production. The use of microorganisms allows large-scale fermentations and the downstream 
purification processes become easier due to the absence of competing pathways [44]. Moreover, 
microorganisms have a primary metabolism similar to plants being able to provide the aromatic 
amino acids and malonyl-CoA as precursor molecules. Therefore, the use of microbial cell factories 
appears to be an ideal solution to industrially produce plant therapeutic polyphenols. 
The most commonly used microorganisms for metabolic engineering purposes are the bacteria 
Escherichia coli and the yeast Saccharomyces cerevisiae. These organisms are very well characterized, 
easy to grow, manipulate and scale-up. S. cerevisiae is a key laboratorial and industrial microorganism 
and represents an excellent chassis for metabolic engineering and synthetic biology approaches. S. 
cerevisiae was the first eukaryotic organism whose genome was fully sequenced [45]. This 
microorganism has been extensively engineered to produce a wide variety of compounds and 
proteins. In addition, the knowledge on its physiology, genetics and fermentation patterns is vast, 
similarly to E. coli. However, it presents some unique characteristics over the bacteria to produce 
plant compounds. Being a eukaryotic organism, it is capable of post-translational modifications such 
as glycosylation and it possesses intracellular compartments similarly to plants. Moreover, S. 
cerevisiae, unlike E. coli, has a food-grade status allowing its use in human nutrition and 
pharmaceuticals [45]. In recent years, many efforts have been developed to heterologously produce 
hydroxycinnamic acids and polyphenols using S. cerevisiae (Table 2). 
2. Genetic Engineering of Saccharomyces Cerevisiae 
The design, construction and optimization of biochemical pathways in S. cerevisiae is mandatory 
to achieve high amounts of heterologous compounds. In the next sections, examples of heterologous 
production of polyphenolic compounds and respective optimizations in S. cerevisiae using synthetic 
biology approaches will be described.  
2.1. Synthetic Biology Tools for Genome Engineering 
S. cerevisiae is easily manipulated through molecular and synthetic biology techniques. The 
classical restriction–ligation-based cloning is being gradually replaced by new methods for the rapid 
design and construction of large biochemical pathways like the “DNA assembler” [46]. The excellent 
homologous recombination (HR) capability of this microorganism facilitates the use of these 
techniques. Two synthetic biology tools that are used to genetically engineer heterologous 
biosynthetic pathways in S. cerevisiae genome are discussed below. 
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Table 2. Production of hydroxycinnamic acids and polyphenols in Saccharomyces cerevisiae. The genes, genetic systems, chassis, chassis modifications, substrates, 
conditions and titers obtained. 
Phenolic 
Compound Genes 
1 Genetic System Chassis/Chassis Modification 2 Substrate 3 Conditions Titer (mg/L) Reference 
Coumaric acid FjTAL  One copy genome integration  
S. cerevisiae CEN.PK102-5B/Aromatic 
amino acids overproducing strain Synthetic fed-batch medium 
Microtiter 
plates  1900 [47] 
Coumaric acid FjTAL  One copy genome integration 
S. cerevisiae CEN.PK102-5B/Knockout 
of the downregulated transporter 
TAT1 
Glucose (10 g/L)  Fed-batch 2400 [48] 
Coumaric acid FjTAL, xylose utilization genes  
One copy genome 
integration 
S. cerevisiae CMB.GS010/Aromatic 
amino acids overproducing strain  Xylose (15 g/L)  
Batch 
bioreactor 242 [49] 
Coumaric acid AtPAL, AtC4H One copy genome integration 
S. cerevisiae IMX/Aromatic amino 
acids overproducing strain; 
Overexpression of CYB5 and 
expression of AtCPR to enhance 
cytochrome P450 activity 
Glucose (20 g/L) Fed-batch  12500 [50] 
Caffeic acid RtTAL, PaHpaB, SeHpaC  Episomal plasmid  S. cerevisiae BY4741/- Tyrosine (0.5 g/L) Shake flask  289.4 [51] 
Caffeic acid RcTAL, AtC3H, AtCPR  
One copy genome 
integration  
S. cerevisiae BY4742/Aromatic amino 
acids overproducing strain; 
Expression of AtCPR to enhance 
cytochrome P450 activity 
Glucose (40 g/L) Shake flask  11.4 [52] 
Resveratrol Ph4CL216, VvVST1  Episomal plasmid S. cerevisiae FY23/- Coumaric acid (10 mg/L)  Shake flask  0.0014 [53] 
Resveratrol Nt4CL2, VvSTS  One copy genome integration  S. cerevisiae CEN-PK113-3B/- Coumaric acid (820 mg/L) Shake flask  5.8 [54] 
Resveratrol At4CL1, VvSTS  Episomal plasmid S. cerevisiae strain isolated from a Brazilian sugar cane plantation.  Coumaric acid (2.46 g/L) Shake flask  391 [55] 
Resveratrol At4CL1, AhSTS  Episomal plasmid  S. cerevisiae W303-1A/PAD knock-out Coumaric acid (16 mg/L)  Shake flask  3.1 [56] 
Resveratrol 
At4CL1 and 
VvSTS fusion 
protein  
One copy genome 
integration 
S. cerevisiae WAT11/Expression of 
araE transporter Coumaric acid (10 mg/L) every 24h Shake flask  2.3 [57] 
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Table 2. Cont. 
Resveratrol 
RtPAL, 
AtC4H, 
At4CL1, 
AhSTS  
Episomal 
plasmid 
S. cerevisiae W303-
1A/Overexpression of 
ACC1  
Tyrosine (2.17 g/L) Batch bioreactor  5.8 [58] 
Resveratrol 
At4CL1 
and VvSTS 
synthetic 
scaffold  
Episomal 
plasmid  S. cerevisiae WAT11/- Coumaric acid (20 mg/L) Shake flask  14.4 [59] 
Resveratrol 
HaTAL, 
At4CL1, 
VvVST  
Multiple 
copy 
genome 
integration  
S. cerevisiae CEN.PK102-
5B/Aromatic amino acids 
overproducing strain  
Glucose  
(40 g/L) Fed-batch bioreactor  531.4 [60] 
Resveratrol 
AtPAL, 
AtC4H, 
At4CL2, 
VvVST1  
Multiple copy genome 
integration 
S. cerevisiae CEN.PK102-5B/Aromatic amino acids overproducing strain; 
Expression of AtCPR and CYB5 to enhance cytochrome P450 activity 
Glucose  
(88 g/L) 
Fed-batch 
bioreactor 
800 
[61] Pinostilbene 
AtPAL, 
AtC4H, 
At4CL2, 
VvVST1, 
VvROMT 
1.96 
Pterostilbene  
AtPAL, 
AtC4H, 
At4CL2, 
VvVST1, 
VvROMT 
34.9 
Pterostilbene  
At4CL, 
VvSTS, 
VvROMT 
Episomal plasmids  S. cerevisiae WAT11 Coumaric acid (10 mg/L) 
Shake 
flask 2.2 [62] 
Naringenin 
chalcone 
RtPAL, 
At4CL1, 
HaCHS 
Episomal plasmids S. cerevisiae AH22/PAD knock-out Galactose  (20 g/L) 
Shake 
flask 7 [63] 
Naringenin 
AtPAL, 
AtCHI, 
AtCHS, 
At4CL3, 
AtTAL, 
AtC4H, 
AtCHS3 
One copy genome 
integration 
S. cerevisiae CEN.PK717.5A/Aromatic amino acids overproducing strain; 
Expression of AtCPR to enhance cytochrome P450 activity 
Glucose  
(20 g/L) 
Batch 
bioreactor 108.9 [64] 
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Table 2. Cont. 
Naringenin 
PhPAL, 
Gm4CL2, 
GmCHS, 
GmCHI 
One copy genome 
integration 
S. cerevisiae YPH499/Expression of PhCPR to enhance cytochrome P450 
activity 
Phenylalanine  
(1.7 g/L) Shake flask 
8.9 
[65] 
Genistein 
PhPAL, 
Gm4CL2, 
GmCHS, 
GmCHI, GmIFS 
0.1 
Kaempferol 
PhPAL, 
Gm4CL2, 
GmCHS, 
GmCHI, 
GmF3’H, StFLS 
1.3 
Quercetin 
PhPAL, 
GmC4H, 
Gm4CL2, 
GmCHS, 
GmCHI, 
GmF3’H, StFLS 
0.26 
Naringenin FjTAL, Pc4CL, PhCHS, MsCHI 
One copy genome 
integration 
S. cerevisiae CEN.PK102-5B/Aromatic amino acids overproducing strain; 
Expression of CrCPR to enhance cytochrome P450 activity 
Synthetic fed-
batch 
medium 
Microtiter 
plates 
1.55 
[66] 
Liquiritigenin 
FjTAL, Pc4CL, 
PhCHS, 
MsCHI, 
AmCHR 
5.31 
Kaempferol 
FjTAL, Pc4CL, 
PhCHS, 
MsCHI, 
AmF3H, AtFLS 
26.57 
Resokaempferol 
FjTAL, Pc4CL, 
PhCHS, 
AmCHR, 
MsCHI, 
AmF3H, AtFLS 
0.51 
Quercetin 
FjTAL, Pc4CL, 
PhCHS, 
MsCHI, 
AmF3H, AtFLS, 
PhFMO 
20.38 
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Table 2. Cont. 
Fisetin 
FjTAL, Pc4CL, 
PhCHS, 
AmCHR, 
MsCHI, 
AmF3H, AtFLS, 
PhFMO 
    1.65  
Naringenin 
FjTAL, At4CL2, 
HaCHS, 
MsCHI 
One copy genome 
integration 
S. cerevisiae BY4741/Aromatic amino acids overproducing strain; 
Overexpression of ACC1 and decrease of the flux towards fatty acid 
biosynthesis 
Sucrose  
(10 g/L) Shake flask 90 [67] 
Kaempferol 
EgPAL, 
EgC4H, Eg4CL, 
EgCHS, EgCHI, 
AtF3H, PdFLS 
One copy genome 
integration S. cerevisiae W303-1A/Increased flux towards malonyl-CoA synthesis 
Glucose (20 
g/L) 
Fed-batch 
bioreactor  66.3 [68] 
Naringenin FjTAL, At4CL1, HaCHS, PhCHI Episomal plasmids S. cerevisiae BY4741/Aromatic amino acids overproducing strain 
Glucose (20 
g/L) Shake flask 220 [69] 
Kaempferol 
FjTAL; At4CL1; 
HaCHS; 
CuF3H, AtFLS 
    86  
Naringenin 
AtPAL, AtTAL, 
AtC4H, 
At4CL3, 
AtCHI, 
AtCHS3, SfFPT 
One copy genome 
integration and episomal 
plasmids 
S. cerevisiae IMK393/Aromatic amino acids overproducing strain; 
Expression of AtCPR to enhance cytochrome P450 activity; replacement 
of TSC13 by an orthologue gene 
Glucose  
(20 g/L) Shake flask 100 [70] 
8-
Prenylnaringenin      0.12  
Liquiritin 
GuPAL, 
GuC4H, 
Gu4CL1, 
GuCHS, 
GuCHR, 
GuCHI, 
GuUGT 
Episomal plasmids  S. cerevisiae WM4-3 Glucose (20 g/L) 
Fed-batch 
bioreactor  0.42 [71] 
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Table 2. Cont. 
Phloterin 
AtPAL, 
AmmC4H, 
At4CL2, 
HaCHS, 
ScTSC13  
Episomal plasmids  
S. cerevisiae BG/Overexpression of ScCPR1 to enhance cytochrome P450 
activity 
Glucose (20 
g/L) Microtiter plates 
42.7 
[72] 
Pinocembrin 
AtPAL, 
At4CL2, 
HaCHS, 
ScTSC13 
 2.6 
Phlorizin  
AtPAL, 
AmmC4H, 
At4CL2, 
HaCHS, 
ScTSC13, 
PycUGT 
Episomal plasmids  S. cerevisiae BG/Overexpression of ScCPR1 to enhance cytochrome P450 activity 
Glucose (20 
g/L) Microtiter plates 
65 
[72] 
Nothofagin 
AtPAL, 
AmmC4H, 
At4CL2, 
HaCHS, 
ScTSC13, 
OsUGT 
59 
Trilobatin 
AtPAL, 
AmmC4H, 
At4CL2, 
HaCHS, 
ScTSC13, 
AtUGT 
32.8 
Naringin 
dihydrochalcone 
AtPAL, 
AmmC4H, 
At4CL2, 
HaCHS, 
ScTSC13, 
AtUGT, 
CmRHAT, 
AtRHM 
11.6 
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Table 2. Cont. 
3-
Hydroxyphloretin 
AtPAL, 
AmmC4H, 
At4CL2, 
HaCHS, 
ScTSC13, 
CsCH3H, 
AtATR 
    28.8  
Afzelechin 
AtPAL, 
AnmC4H, 
MsCHI, 
At4CL2, 
MdF3H, 
AaDFR, VvLAR 
One copy genome 
integration 
S. cerevisiae BG/Expression of AtCPR1 to enhance cytochrome P450 
activity 
Glucose (20 
g/L) 
Microtiter 
plates 
~80 
4 
[73] 
Catechin 
AtPAL, 
AnmC4H, 
MsCHI, 
At4CL2, 
MdF3H, 
MdF3’H, 
AaDFR, VvLAR 
~90 
4 
Gallocatechin 
AtPAL, 
AnmC4H, 
MsCHI, 
At4CL2, 
MdF3H, 
MdF3’5’H, 
AaDFR, VvLAR 
~25 4 
Pelargonidin-3-O-
glucosidase  
AtPAL, 
AnmC4H, 
MsCHI, 
At4CL2, 
MdF3H, 
AaDFR, 
PhANS, 
DcA3GT 
0.85 
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Table 2. Cont. 
Cyanidin-3-O-
glucosidase 
AtPAL, 
AnmC4H, 
MsCHI, 
At4CL2, 
MdF3H, 
MdF3’H, 
AaDFR, 
PhANS, 
FaA3GT     
1.55 
 
Delphinidin-3-O-
glucosidase 
AtPAL, 
AnmC4H, 
MsCHI, 
At4CL2, 
MdF3H, 
MdF3’5´H, 
AaDFR, 
PhANS, 
FaA3GT 
1.86 
Apigenin 
AtC4H, 
Pc4CL2, 
PehCHI, 
PehCHS, PcFSI 
Episomal plasmids  S. cerevisiae INVSc1/Overexpression of ScCPR and AnmCPR to enhance cytochrome P450 activity 
Cinnamic 
acid (74 
mg/L) 
Shake flask 
0.4 
[74] 
Naringenin 
AtC4H, 
Pc4CL2, 
PehCHI, 
PehCHS, PcFSI 
0.07 
Luteolin 
AtC4H, 
Pc4CL2, 
PehCHI, 
PehCHS, PcFSI 
1.1 
Eriodictoyl 
AtC4H, 
Pc4CL2, 
PehCHI, 
PehCHS, PcFSI 
2.5 
Pinocembrin 
AtC4H, 
Pc4CL2, 
PehCHI, 
PehCHS, PcFSI 
1.4 
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Table 2. Cont. 
Naringenin FjTAL, At4CL1, AtCHS, AtCHI 
One copy genome 
integration 
S. cerevisiae BY4741/Increased flux towards aromatic amino acids and 
malonyl-CoA biosynthesis 
Glucose (20 
g/L) Shake flask 
144.1 
[75] 
Kaempferol  
FjTAL, At4CL1, 
AtCHS, AtCHI, 
NtF3H, AtFLS 
168.1 
Quercetin 
FjTAL, At4CL1, 
AtCHS, AtCHI, 
NtF3H, 
PhF3’H, AtFLS 
154.2 
Myricetin 
FjTAL, At4CL1, 
AtCHS, AtCHI, 
NtF3H, 
PhF3’H, 
SlF3’5’H, 
AtFLS 
145 
Pelargodinin  
FjTAL, At4CL1, 
AtCHS, AtCHI, 
NtF3H, AaDFR, 
GeANS 
33.3 
Cyanidin 
FjTAL, At4CL1, 
AtCHS, AtCHI, 
NtF3H, 
PhF3’H, 
GeDFR, GeANS 
31.7 
p-Coumaroyl-3-
hydroxyanthranilic 
acid Nt4CL2, 
CcHCT Episomal plasmids S. cerevisiae CENPK113-5d/ - 
Coumaric 
acid (462 
mg/L) and 
HAA (77 
mg/L) Batch bioreactor 
120 
[38] 
Caffeoyl-3-
hydroxyanthranilic 
acid 
Caffeic acid 
(540 mg/L) 
and HAA (77 
mg/L) 
22 
1 4CL—4-coumarate-CoA ligase; A3GT—anthocyanidin-3-O-glycosyl transferase; ANS—anthocyanidin synthase; C3H—4-coumarate 3-hydroxylase; C4H—
cinnamate-4- hydroxylase; CH3H—chalcone 3-hydroxylase; CHR—chalcone reductase; COMT—caffeic acid O-methyltransferase; CCoAOMT—caffeoyl-CoA O 
methyltransferase; CHI—chalcone isomerase; CHS—chalcone synthase; CURS—curcumin synthase; CUS—curcuminoid synthase; DCS—diketide-CoA synthase; 
DFR—dihydroflavonol-4-reductase; F3H—flavanone 3-hydroxylase; F3’H—flavonoid-3’-hydroxylase; F3´5´H—flavonoid-3’,5’-hydroxylase; FLS—flavonol 
synthase; FMO—cytochrome P450 flavonoid monooxygenases; FPT—flavonoid prenyltransferase; FSI—flavone synthase I; HCT—hydroxycinnamoyl-CoA:quinate 
hydroxycinnamoyltransferase; HpaB and HpaC—4-hydroxyphenylacetate 3-hydroxylase; IFS—isoflavone synthase; LAR—leucoanthocyanidin reductase; PAL—
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phenylalanine ammonia lyase; RHAT—flavanone 2-O-rhamnosyltransferase; RHM—rhamnose synthase; ROMT—resveratrol O-methyltransferase; STS—stilbene 
synthase; TAL—tyrosine ammonia lyase; UGT—isoflavonoid 7-O-glycosyltransferase; VST—resveratrol synthase; Aa—Anthurium andraeanum; Ah—Arachis 
hypogaea; Am—Astragalus mongholicus; Amm—Ammi majus; Anm—Antirrhinum majus; At—Arabidopsis thaliana; Cc—Cynara cardunculus; Cm—Citrus maxima; Cr—
Catharanthus roseus; Cs—Cosmos sulphureus Cu—Citrus unshiu; Dc—Dianthus caryophyllus; Eg—Erigeron breviscapus; Fa—Fragaria ananassa; Fj—Flavobacterium 
johnsoniaeu; Ge—Gerbera specie; Gm—Glycine max; Gu—Glycyrrhiza uralensis; Ha—Hypericum androsaemum; Hg—Hyperricum androsaemum; Md—Musca domestica; 
Ms—Mendicago sativa; Nt—Nicotiana tabacum; Os—Oriza sativa; Pa—Pseudomonas aeruginosa; Pc—Petroselinum crispum; Pd—Populus deltoides; Peh—Petunia hybrida; 
Ph—Populus hybrid; Pyc—Pyrus communis; Rc—Rhodobacter capsulatus; Rt—Rhodosporidium toruloides; Sc—Saccharomyces cerevisiae; Se—Salmonella enterica; Sf—Sophora 
flavescens; Sl—Solanum lycopersicum; St—Solanum tuberosum; Vv—Vitis vinifera.2 Chassis modifications in addition to pathway integration when applied. ACC—
acetyl-CoA carboxylase; araE—arabinose-H+ transporter, CPR—cytochrome P450 reductase; PAD—phenylacrylic acid decarboxylase; TAT1—Tyrosine and 
tryptophan amino acid transporter; CYB5—cytochrome B5; TSC13—double-bond reductase involved in fatty acid synthesis. 3 Synthetic fed-batch medium contains 
a glucose polymer which is converted into glucose monomers by glucose releasing enzymes during the fermentation process; HAA—hydroxyanthranilic acid. 4 
Values extrapolated from graphics.
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Genome Integration 
Most of the metabolic engineering approaches in S. cerevisiae used high copy number 2 micron 
(2µ) episomal plasmids. In particular, high copy plasmids can be maintained at 10–80 copies per cell 
[76] providing a convenient platform for the overexpression of heterologous genes. However, there 
are inherent problems associated with episomal plasmids, namely their instability, variations in gene 
expression within a population, as well as the high maintenance costs to ensure the selective pressure 
[77]. The genomic integration of entire biosynthetic pathways appears as an alternative to the use of 
episomal plasmids since it allows for the stable expression of the heterologous pathways. 
Nevertheless, integration is unsuitable as an overexpression system because only one copy can be 
integrated into the yeast genome. Although the multi-copy integration of biochemical pathways is 
essential, it is still a challenging strategy. The delta integration strategy was developed to achieve the 
multi-copy integration of heterologous genes by HR at Ty retrotransposon delta sites, a set of 
repetitive regions in yeast genome. Using this strategy, a heterologous biosynthetic pathway can be 
inserted in a multi-copy way allowing for the overexpression of recombinant enzymes as it occurs 
with episomal plasmids [78,79]. For instance, Li et al. [60] used a multiple integrative plasmid to 
engineer yeast for the de novo biosynthesis of resveratrol. The authors determined the heterologous 
gene copy number by qPCR. The strain containing multiple copies of the pathway produced 36 times 
more resveratrol than the strain containing only one copy, although only eight pathway copies were 
integrated into the yeast genome [60]. 
With the development of new molecular biology techniques, such as the Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR)-associated caspase 9 endonuclease (Cas9) system, it 
became possible to modify the genome of different microorganisms in a more efficient way. The 
CRISPR-Cas9 system was first introduced in S. cerevisiae by DiCarlo et al. [80]. Nowadays, this system 
has been routinely used for carrying out high-efficiency gene knock-ins and knock-outs. These 
modifications are performed without the use of selection markers since the combination of double 
strand breaks (DSB), caused by CRISPR technology, and the HR capability of yeast has almost total 
effectiveness. The short DNA donor oligos sharing homology with a target site can serve as the simplest 
repair template resulting in an efficient HR [80]. Therefore, the combination of CRISPR-Cas9 with HR 
capability represent a powerful technique to genetically engineer yeast. Shi et al. [81] developed a novel 
method that combined CRISPR-Cas9 and delta integration (Figure 4). The delta integration CRISPR-
Cas9 method is a useful strategy to stably integrate multiple copies of large biochemical pathways 
without the use of selection markers. Using this strategy, the researchers integrated 18 copies of a 24 kb 
fragment in the yeast genome in a single step. Although this technique has not been used for polyphenol 
pathway engineering in yeast, it may be very useful in future experiments. 
 
Figure 4. Multi-copy integration of a heterologous pathway at delta sites (δ) mediated by the 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated caspase 9 
endonuclease (Cas9) [63]. DSB—Double strand break. 
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2.2. Pathway Enzyme Engineering 
Finding the right enzyme combination is a key step in the genetic engineering of any 
heterologous pathway. The enzymes for producing polyphenols in an engineered yeast should be 
carefully selected to ensure a metabolic balance between all the intermediary reactions and 
consequently obtain higher production yields. Moreover, the use of enzymes that catalyze more than 
one reaction may decrease the metabolic burden caused to the host, hence resulting in an enhanced 
production. As previously mentioned, PAL is the first enzyme of the phenylpropanoids pathway. 
Some PALs also have TAL activity, converting tyrosine directly into p-coumaric acid. The use of these 
enzymes allows the production of p-coumaric acid without requiring C4H (a membrane-bound 
cytochrome P450-dependent enzyme). This represents an advantage since the native cytochrome 
P450 activity could not be enough to support P450-dependent plant enzymes. Trantas et al. [65] 
engineered a set of yeasts to produce flavonoids and stilbenoids using phenylalanine as the initial 
precursor. Depending on the final phenylpropanoid, the constructed pathways contained four to 
eight enzymatic steps. In addition, the researchers tested if the co-expression of a heterologous 
cytochrome P450 reductase (CPR) would enhance the activity of the cloned C4H. When the CPR was 
co-expressed the production of p-coumaric acid was enhanced by four times. This indicated that the 
activity of the endogenous yeast CPR was not sufficient to support the maximum substrates fluxes 
through C4H.  
The 4CL enzymes family catalyzes the conversion of p-coumaric acid, ferulic acid and caffeic 
acid to the respective CoA esters. Furthermore, 4CL has been shown to occur in multiple isoforms 
with distinct substrate affinities [82]. In the heterologous production of flavonoids and stilbenoids in 
S. cerevisiae, 4CLs from Arabidopsis thaliana are the most commonly used [55,56,83]. A. thaliana 
possesses four isoforms of 4CL (At4CL1, At4CL2, At4CL3 and At4CL4). From the expression patterns 
and phylogenetic similarity, only At4CL3 is suggested to play a role in flavonoid biosynthesis. 
At4CL1 and At4CL2 are presumed to be involved in the lignin production [82]. Li et al. [60] evaluated 
if the use of different A. thaliana 4CL isoforms (At4CL1 and At4CL2) would have an impact on the 
production of resveratrol by the engineered yeasts. The results confirmed that At4CL1 resulted in 
slightly higher resveratrol titers than At4CL2. These results confirmed that At4CL1 has higher 
activity towards p-coumaric acid as described by Ehlting et al. [82]. Altogether, these results 
demonstrated that choosing the right enzymes combination is a key step to produce heterologous 
compounds such as polyphenols in yeast.  
The expression of heterologous genes in S. cerevisiae can lead to translation errors, frameshifting 
events, stalling or premature translational termination due to the existence of rare codons. 
Consequently, it can result in the expression of a non-functional enzyme. To overcome that, codon 
optimization must be considered to optimize the heterologous production of polyphenols. For 
instance, in the work developed by Wang et al. [57], the enzyme TAL from Rhodobacter sphaeroides did 
not show in vivo activity in S. cerevisiae. In contrast, the use of a codon-optimized TAL enabled the 
resveratrol biosynthesis in the engineered yeast. 
Spatial Location of Heterologous Enzymes 
Organelles are important supplies of cofactors. In mitochondria, the pool of acetyl-CoA is higher 
than in cytoplasm [84]. This may be advantageous for the expression of enzymes related with 
polyphenol synthesis since malonyl-CoA plays a key role in the biosynthetic pathway. In higher 
plants, polyphenol biosynthetic enzymes are co-localized and assembled in protein complexes and 
the metabolic channeling effect decreases the formation of by-products. In analogy, 
compartmentalization or scaffolding the polyphenol enzymes in yeast may have a positive effect on 
the enzymatic activity and therefore on the polyphenol production. The compartmentalization of the 
phenylpropanoid pathway has never been achieved. However, this strategy was already used to 
produce terpenoids in genetically modified yeasts yielding good results [85]. For this reason, the 
compartmentalization of the polyphenol pathway appears as a must-try in future works. 
Closely locating two active sites or channeling the intermediate compounds between the 
enzymes may also improve the metabolic efficiency of the heterologous enzymes. This can be 
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accomplished by using fusion proteins or by constructing synthetic scaffolds, respectively. Zhang et 
al. [86] constructed a translational fusion protein of 4CL from A. thaliana and STS from Vitis vinifera 
(4CL:STS). The fusion protein was constructed by replacing the stop codon of the 4CL gene by a three-
amino acid linker and the STS sequence. Resveratrol biosynthesis in yeasts transformed with 4CL:STS 
increased 15-fold as compared with the transformants co-expressing 4CL and STS. Moreover, Wang 
and Yu [59] constructed synthetic scaffolds to recruit At4CL1 and VvSTS to improve resveratrol 
production. The scaffolds interacted with the heterologous enzymes through the small peptide 
ligands that were expressed in the end of each heterologous gene. This strategy allowed the substrate 
channeling between the two enzymes. The engineered strain produced five-fold more resveratrol 
over the one where scaffolds were not used. In addition, the production of resveratrol was 2.7-fold 
improved comparing with the production obtained using fusion proteins [86], thus suggesting more 
effectiveness when scaffolds are used. 
2.3. Strain Optimization 
The optimization of the heterologous pathways is a key step for the development of efficient 
yeast cell factories to produce polyphenols. Besides that, the yeast chassis should also be genetically 
engineered to maximize the production yields. These genetic modifications may include the 
overexpression or deletion of endogenous genes to increase the polyphenol precursors supply or to 
prevent the intermediate consumption. These modifications allow the production of polyphenols in 
higher yields from simple substrates such as glucose, which represents a big step towards an 
industrial application. In this section, strategies used to improve the yeast chassis for polyphenol 
production are described. 
2.3.1. Amino Acids Overproducing Strains 
In order to improve the production of the desired compounds in engineered cells it is important 
to perform genetic modifications to improve the amounts of precursors available. The modifications 
could be deletions of genes involved in the deviation of a precursor and consequently, in the 
production of by-products or the overexpression of genes involved in the precursor biosynthesis. The 
aromatic amino acids precursors of the phenylpropanoids acids are not produced in high amounts 
by S. cerevisiae, thus representing a limiting step for the polyphenol production [50]. To achieve a high 
polyphenol yields, the media can be supplemented with precursors such as aromatic amino acids or 
hydroxycinnamic acids. However, this makes the process expensive for industrial applications. 
Therefore, the development of strains capable of converting glucose or other simple carbon sources 
to polyphenols also represents an attractive engineering strategy. The aromatic amino acid 
biosynthesis is a branched pathway regulated at the transcriptional, translational and allosteric levels. 
At the allosteric level, the effector molecules are the aromatic amino acids tyrosine and phenylalanine. 
For example, the reactions catalyzed by CM and 3-deoxy-D-arabino-heptulosonate-7-phosphate 
synthase (DAHPS), enzymes involved in the shikimate pathway (Figure 2), are feedback-inhibited 
by tyrosine and phenylalanine [87]. Koopman et al. [64] constructed a mutated S. cerevisiae strain 
capable of overproducing aromatic amino acids by replacing the DAHPS gene, for a feedback-
insensitive version. Consequently, the replacement of this gene by an insensitive version was 
important to maintain the amino acids production. Moreover, the deletion of phenylpyruvate 
decarboxylase (PDC) that was responsible for the conversion of phenylpyruvate, the precursor of 
phenylalanine, into phenylacetaldehyde, was important to prevent the pathway deviation. This 
optimized strain produced larger amounts of naringenin comparatively to the non-optimized strain 
[64]. In a different study, Li et al. [60] constructed a pathway for the de novo biosynthesis of 
resveratrol from glucose, and to improve the flux towards aromatic amino acids, the researchers 
developed a feedback-inhibition-resistant strain overexpressing CM and DAHPS. This resulted in 
4.85 mg/L resveratrol, a titer 1.8 times higher than the one obtained without the overexpressed genes 
[60]. More recently, a strain highly adapted to produce p-coumaric acid was developed by performing 
several modifications in yeast chassis to program the carbon metabolism towards the aromatic amino 
acid biosynthesis [50]. The heterologous pathway was composed by PAL and C4H from A. thaliana 
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and the native cytochrome (CYB5) and the A. thaliana P450 reductase were also overexpressed to 
improve the cytochrome P450 activity. The chassis modifications also included the expression of a 
feedback insensitive DAHPS and CM. Moreover, three native shikimate pathway genes and a 
heterologous version of prephenate dehydrogenase (PDH) were overexpressed to increase the total 
shikimate pathway activity. In order to improve the shikimate precursor E4P availability, a 
heterologous phosphoketalose-based pathway was inserted. In addition, to optimize the carbon flux 
from glycolysis towards the aromatic amino acid biosynthesis, promoters of key node genes were 
replaced. PDC was also deleted to prevent pathway deviation. The final strain produced 12.5 g/L of 
p-coumaric acid, by far the highest titer reported.  
The expression of heterologous metabolic pathways impacts the cellular physiology and 
frequently triggers a stress response. The identification of the affected pathways and then the genetic 
modification of target genes can improve the titers of the desired product [88]. Rodriguez et al. [48] 
found after transcriptome and metabolome computational analyses significant expression changes in 
a set of genes in an engineered yeast strain able to produce p-coumaric acid. Genes involved in the 
transport of amino acids, polyamines and sugars were found to be downregulated. Then, the 
researchers knocked out these specific genes to evaluate its effect in p-coumaric acid production titers. 
The deletions improved the synthesis of the polyphenol precursor. The highest improvement (up to 
50%) was obtained by the deletion of tyrosine and tryptophan amino acid transporter 1 (TAT1). The 
authors hypothesized that this deletion resulted in a decrease of the leakage of tyrosine from the cells, 
thus being more available for the production of p-coumaric acid [48]. 
2.3.2. Extender Substrates Availability 
To produce one polyphenol molecule, it is necessary to have at least one molecule of malonyl-
CoA since this molecule acts as an extender molecule in the final reactions. However, the levels of 
malonyl-CoA inside the cell are low, representing a limiting step in the heterologous production of 
polyphenols. Malonyl-CoA is naturally synthesized by acetyl-CoA carboxylase (ACC). This enzyme 
catalyzes the carboxylation of acetyl-CoA to malonyl-CoA in microorganisms. The malonyl-CoA is 
mainly used for the production of fatty acids and phospholipids, leaving only a very limited amount 
available for the production of secondary metabolites [89]. 
Shin et al. [58] investigated the production of resveratrol from supplemented tyrosine. They 
introduced PAL, C4H, 4CL and STS genes into S. cerevisiae. In addition, the authors replaced the ACC 
native promoter by a stronger inducible promoter (pGAL1-galactose inducible promoter). The 
overexpression of the ACC gene resulted in a 1.3-fold increase in resveratrol concentration [58]. The 
ACC enzyme can be targeted for degradation via phosphorylation by sucrose non-fermenting protein 
1 (Snf1p) in yeast decreasing the endogenous pool of malonyl-CoA inside the cell [90]. Li et al. [60], 
apart from the aforementioned resveratrol pathway multi-copy integration and DAHPS and CM 
overexpression, also used a strategy to improve the intracellular malonyl-CoA bioavailability. This 
strategy included the overexpression of a post-translational deregulated ACC. This version of the 
ACC gene was previously described by Shi et al. [91] and it contains two-point mutations in serine 
residues to prevent the phosphorylation and degradation by Snf1p. The engineered strain enhanced 
the productivity by 31% [60]. Afterwards, the same research team [61], applied a more complex 
approach. They changed the heterologous pathway to use phenylalanine instead of tyrosine and 
overexpressed the CPR from A. thaliana and the native CYB5 to enhance the P450 function required 
by C4H. DAHPS and CM were also overexpressed and the PDC was deleted. The shikimate kinase 
from E. coli was also overexpressed to increase the metabolic flux through the shikimate pathway. 
Regarding the malonyl-CoA bioavailability, in addition to the mutated ACC overexpression, the 
acetyl-CoA synthase from Salmonella enterica was also overexpressed. The final strain produced 800 
mg/L of resveratrol in a fed-batch fermentation. This represented by far the highest yield reported 
regarding the polyphenol heterologous production in S. cerevisiae.  
Due to the chemodiversity of polyphenols, other extender substrates may be required to obtain 
the desired final product. With that comes the need to also increase the endogenous production of a 
given functional group, since its intracellular pool in yeast may not be enough to support the specific 
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polyphenol biosynthesis. For instance, Levisson et al. [70] have optimized a S. cerevisiae strain for the 
de novo production of 8-prenylnaringenin. Initially, an amino acids overproducing strain containing 
the naringenin biosynthetic pathway integrated into its genome was transformed with an episomal 
plasmid carrying a prenyltransferase (PT) and a truncated form of 3-methylglutaryl coenzyme A 
reductase (tHMG1). tHMG1 was expressed to increase the prenyl donor (dimethylallyl diphosphate) 
supply and consequently, improved the synthesis of 8-prenylnaringenin. However, the production 
yields were found to be residual. Moreover, the essential gene TSC13 was replaced by the orthologue 
enoyl-CoA reductase (ECR) gene from Malus domestica. TSC13 encodes an enzyme involved in fatty 
acid synthesis and is able to convert p-coumaroyl-CoA into phloretic acid. The replacement of this 
gene was important to overcome the p-coumaroyl-CoA consumption since the ECR gene is not able 
to convert p-coumaroyl-CoA into phloretic acid. Moreover, the TAL gene was integrated into the 
genome of this strain to increase the production by using the two aromatic amino acids as precursors. 
Before integrating the TAL gene, this strain was only using the phenylalanine route to produce the 
desired compound. These modifications resulted in a five-fold improvement of naringenin and 10-
fold improvement of 8-prenylnaringenin productions.  
2.3.3. Transporter Expression 
The transport of small molecules into and out of the cell can be sometimes the biggest limiting 
factor in metabolic engineering. Transporters can maximize the productivity by improving substrate 
uptake or product secretion. The removal of a product with reported antimicrobial activity from the 
intracellular medium will increase the product biosynthesis and decrease the product toxicity for the 
cell and the extraction costs. Polyphenols are characterized to often accumulate in plant vacuoles [92] 
and afterwards be transported to the site of action. However, the mechanism of polyphenol 
transportation is not yet fully understood. Wang et al. [57] expressed the arabinose-H+ transport 
protein (AraE) in a resveratrol engineered yeast. The transporter greatly improved the resveratrol 
synthesis. This suggests that AraE may increase the resveratrol permeability through lipid 
membranes when the concentration inside the cell reaches the threshold. More studies on polyphenol 
transport are required, not only to increase their production but also to enable their extraction as soon 
as an industrial production process is implemented.  
3. Key Messages 
In recent years, the demand for polyphenols by the pharmaceutical industry has increased. 
Consequently, the scientific community has been developing several efforts to establish a stable 
platform for the production of these therapeutic compounds. The use of microbial cell factories is an 
attractive approach due to the low costs, the short production times and the high purity when compared 
to the plant extraction. The advances in the synthetic biology and metabolic engineering fields allowed 
the creation of new and powerful genetic tools. The use of these tools in conjugation with the 
development of computational omics is enabling the genetic engineers to construct host chassis 
increasingly adapted to the production of polyphenols. So far, the different synthetic biology 
approaches used by several researchers have showed significant improvements in the production of 
these compounds using engineered S. cerevisiae. Nevertheless, the implementation of an industrial 
process to produce polyphenols using microbial cell factories still has a long way to go before becoming 
a reality. However, the recently high production of the precursor p-coumaric acid obtained in S. 
cerevisiae [50] opened the door to producing high amounts of polyphenols in the near future. In addition, 
some polyphenols, such as curcuminoids and coumarins, have never been produced in S. cerevisiae 
although the pathways are generally well characterized and have been successfully produced in E. coli 
[39,93]. We believe that these pathways can be effectively expressed in yeast, possibly with higher titers, 
and therefore should be explored. Overall, this review provided an overview of diverse recent advances 
in the heterologous production of polyphenols in S. cerevisiae. Moreover, an outline of different 
synthetic biology methodologies that can be useful to further optimize S. cerevisiae towards the 
production of high amounts of several polyphenols was herein provided. In summary, we believe that 
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after several optimizations of the host chassis, large amounts of polyphenols could be industrially 
produced in a fast, efficient and environmentally friendly process. 
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